Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Product Portfolio
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) completed Phase 1 for Liv18, finalizing product development, packaging, and initial commercial setup ahead of schedule. U.S. production begins April 2026 at GMP-certified, FDA-registered, UL-audited facilities to reduce tariff exposure and improve supply chain efficiency.
The company projects over $5M in annual revenue for Liv18 at approximately 75% gross margins, driven by a direct-to-consumer model and targeted advertising; early U.S. traction from other products informs commercial expectations.
Positive
- Phase 1 completed ahead of schedule
- U.S. production starting in April 2026
- Manufacturing at GMP/FDA/UL certified facilities
- Projected >$5M annual revenue for Liv18
- Approximately 75% gross margins expected
- Direct-to-consumer model with scalable marketing
Negative
- None.
News Market Reaction – COSM
In the Apr 20 session, COSM declined 5.59%, reflecting a notable negative market reaction. Argus tracked a peak move of +5.1% during that session. Argus tracked a trough of -15.4% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Crypto,clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 24 | Capacity expansion update | Positive | +2.5% | Completed Phase I manufacturing upgrades positioning for >$10M recurring annual gross profit. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
For similar 'crypto,clinical trial' tagged operational expansion news, COSM previously saw a modest positive reaction, indicating the market has historically responded constructively to capacity and production milestones.
Over recent quarters, Cosmos Health has highlighted expansion in manufacturing capacity, proprietary brands, and U.S. nutraceutical launches. A prior Phase I manufacturing upgrade positioned the company for over $10 million in recurring annual gross profit at full capacity. Subsequent updates reported record FY 2025 revenue of $65.27M and strong U.S. growth initiatives. Today’s Liv18™ update fits this pattern of scaling high-margin, clinically supported supplements within the U.S. market.
Key Terms
gmp-certified medical
fda-registered regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Phase 1 complete: product development, packaging, and initial commercial setup finalized ahead of schedule
Production commencing April 2026: GMP-certified, FDA-registered, UL-audited U.S. manufacturing - mitigating tariff risk
$5M + projected annual revenue: Liv18™ expected to generate over$5 million annually at approximately75% gross marginsDirect-to-consumer model: scalable DTC strategy with targeted advertising and disciplined capital allocation
Early U.S. traction confirmed: commercial indicators from existing products shaping revenue expectations and go-to-market strategy
CHICAGO, IL / ACCESS Newswire / April 20, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today provided a commercial and financial update on Liv18™, its clinically validated liver health supplement, as the Company accelerates its expansion across the United States.
The Company has successfully completed Phase 1 execution for Liv18™ (defined as product development, packaging, and initial commercial setup) ahead of schedule. Production is expected to commence in April 2026, with initial market rollout to follow shortly thereafter.
Liv18™ will be manufactured in the United States at GMP-certified, FDA-registered, and UL-audited facilities, reflecting high standards of quality, safety, and regulatory compliance. This localized approach enhances supply chain efficiency, reduces complexity, mitigates tariff exposure, and supports scalable U.S. growth.
Based on planned investments in advertising, customer acquisition, and business development, along with early U.S. commercial traction from other Cosmos Health products, the Company expects Liv18™ to generate over
Liv18™ is expected to represent a meaningful incremental revenue stream and a high-margin contribution, supporting a significant uplift in overall profitability as the Company expands its U.S. operations.
The Company continues to prioritize the United States as a key strategic growth market and is making targeted investments to drive scalable growth.
Greg Siokas, CEO of Cosmos Health, stated: "The completion of Phase 1 execution for Liv18™ is a significant milestone - and one that is ahead of schedule - as we prepare for its commercial rollout in the United States. We expect Liv18™ to be a meaningful incremental revenue driver, with high margins expected to support a significant uplift in overall profitability. The U.S. is a key strategic priority for Cosmos Health, and we are actively investing to accelerate growth and enhance profitability."
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
SOURCE: BDG Communications
View the original press release on ACCESS Newswire